Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients

2.

Hematocrit Stabilized in Polycythemia Vera Under Novel Hepcidin Mimetic Treatment.

3.

Global warming could be driving up women's cancer risk, find researchers

4.

In KRAS-mutated non-small cell lung cancer, glecirasib exhibits promising efficacy.

5.

CAR Natural Killer Cell Therapy Shows Promise in B-Cell Lymphomas


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot